PMID- 30648737
OWN - NLM
STAT- MEDLINE
DCOM- 20200207
LR  - 20211204
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 105
IP  - 5
DP  - 2019 May
TI  - Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic 
      Migraine.
PG  - 1121-1129
LID - 10.1002/cpt.1356 [doi]
AB  - Migraine is a prevalent, disabling neurological disorder involving the 
      trigeminovascular system. Previous treatments were either originally intended for 
      other conditions and/or associated with intolerable adverse effects (AEs). 
      Calcitonin gene-related peptide (CGRP) is the most prevalent neuropeptide in the 
      trigeminal afferent neurons and plays a significant role in pain sensitization 
      central to migraine. The CGRP antagonists (gepants and monoclonal antibodies) are 
      the first treatments created specifically for migraine, modulating pain signaling 
      pathways and alleviating migraine attacks and recurrences. With their efficacy in 
      several clinical trials and relatively fewer AEs, the CGRP antagonists show great 
      promise for use in episodic migraine.
CI  - (c) 2019 The Authors Clinical Pharmacology & Therapeutics (c) 2019 American Society 
      for Clinical Pharmacology and Therapeutics.
FAU - Yuan, Hsiangkuo
AU  - Yuan H
AD  - Jefferson Headache Center, Thomas Jefferson University, Philadelphia, 
      Pennsylvania, USA.
FAU - White, Courtney S
AU  - White CS
AD  - Jefferson Headache Center, Thomas Jefferson University, Philadelphia, 
      Pennsylvania, USA.
FAU - Silberstein, Stephen D
AU  - Silberstein SD
AD  - Jefferson Headache Center, Thomas Jefferson University, Philadelphia, 
      Pennsylvania, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190318
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Calcitonin Gene-Related Peptide Receptor Antagonists)
RN  - 0 (Dipeptides)
RN  - 0 (Piperazines)
RN  - 0 (Quinazolines)
RN  - JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
RN  - WOA5J8TX6M (olcegepant)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Calcitonin Gene-Related Peptide/*antagonists & inhibitors/metabolism
MH  - Calcitonin Gene-Related Peptide Receptor Antagonists/*therapeutic use
MH  - Dipeptides/therapeutic use
MH  - Humans
MH  - Migraine Disorders/*drug therapy/physiopathology
MH  - Piperazines
MH  - Quinazolines/therapeutic use
EDAT- 2019/01/17 06:00
MHDA- 2020/02/08 06:00
CRDT- 2019/01/17 06:00
PHST- 2018/10/08 00:00 [received]
PHST- 2018/11/30 00:00 [accepted]
PHST- 2019/01/17 06:00 [pubmed]
PHST- 2020/02/08 06:00 [medline]
PHST- 2019/01/17 06:00 [entrez]
AID - 10.1002/cpt.1356 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2019 May;105(5):1121-1129. doi: 10.1002/cpt.1356. Epub 2019 
      Mar 18.